

EXPRESS MAIL CERTIFICATE

Date: 10/25/02
I hereby certify that on the date indicated on this paper or
fee was deposited with the U.S. Postal Service and that it was
expressed for delivery to the Assistant Commissioner for
Patents, Washington, DC 20231 by "Express Mail Post Office
to Addressee" service.

Name (Print)

Signature

208553629 US

#3 1623

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT
ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR
DEPOSIT ACCOUNT NO. 04-0100

Customer No.:



07278

PATENT TRADEMARK OFFICE

Docket No.: 4168/1J672-US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jian-Qiang FAN; Satoshi IISHII;

Serial No.: 09/927,285

Confirmation No.:

Filed: August 10, 2001

For: METHOD OF ENHANCING LYSOSOMAL ALPHA-GALACTOSIDASE A

RECEIVED

OCT 30 2002

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a copy of Form
PTO-1449 and copies of the documents listed thereon.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each

document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

This submission is filed before a first action on the merits has been mailed. It is believed no fees are owed. However, the Commissioner is authorized to charge the fees required in connection with this Statement to Deposit Account No. 04-0100.

A concise explanation of the relevance of the foreign language document (reference 3 herein) as required by 37 CFR 1.98 is provided. This reference describes an increase in beta-Gal activity in gangliosidosis disease patient's cells by treatment with galactose. A translation of the description of Figure 7 (provided by co-inventor Satoshi Ishaii) follows:

“Fig. 7 Effect of galactose on b-Gal activity in lymphoblasts from patients with b-galactosidosis.

The lymphoblasts from patients with b-galactosidosis (GM1-gangliosidosis, Molquio's B disease) and infantile galactosialidosis were cultivated with (dark column) or without (open column) 200 mM galactose for 4 days. The intracellular b-Gal activity was assayed. GM1-Inf: Infant-type GM1-gangliosidosis, GM1-Juv: Juvenile-type GM1-gangliosidosis, GM1-Adu: Adult-type GM1-gangliosidosis, Mor-B: Morquio's B disease,


GS-I: Infant-type galactosialidosis."

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

Dated: October 25, 2002

A handwritten signature in black ink, appearing to read "Paul F. Fehlner", with a horizontal line drawn underneath it.

Paul F. Fehlner, Ph.D.

Registration No. 35,135

Attorney for Applicant(s)

DARBY & DARBY
Post Office Box 5257
New York, NY 10150-5257
(212) 527-7700